{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:36:04Z","timestamp":1787790964936,"version":"build-2784847793"},"reference-count":23,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2014,10,16]],"date-time":"2014-10-16T00:00:00Z","timestamp":1413417600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0109652","type":"journal-article","created":{"date-parts":[[2014,10,20]],"date-time":"2014-10-20T21:02:45Z","timestamp":1413838965000},"page":"e109652","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":13,"title":["Impact of a New Reimbursement Program on Hepatitis B Antiviral Medication Cost and Utilization in Beijing, China"],"prefix":"10.1371","volume":"9","author":[{"given":"Qian","family":"Qiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-wan","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-kun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong-ping","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,10,16]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"6550","DOI":"10.1016\/j.vaccine.2009.08.048","article-title":"Epidemiological serosurvey of hepatitis B in China\u2014declining HBV prevalence due to hepatitis B vaccination","volume":"27","author":"X Liang","year":"2009","journal-title":"Vaccine"},{"key":"ref2","first-page":"3","article-title":"Management of hepatitis B in China","volume":"122","author":"FM Lu","year":"2009","journal-title":"Chin Med J (Engl)"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1472-6963-13-37","article-title":"Direct economic burden of hepatitis B virus related diseases: evidence from Shandong, China","volume":"13","author":"J Lu","year":"2013","journal-title":"BMC Health Serv Res"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1007\/s10620-009-0786-4","article-title":"The societal burden of HBV-related disease: South Korea","volume":"55","author":"BM Yang","year":"2010","journal-title":"Dig Dis Sci"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.cgh.2006.05.016","article-title":"A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update","volume":"4","author":"EB Keeffe","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jhep.2008.10.001","article-title":"EASL Clinical Practice Guidelines: management of chronic hepatitis B","volume":"50","year":"2009","journal-title":"J Hepatol"},{"key":"ref7","first-page":"13","article-title":"The guideline of prevention and treatment for chronic hepatitis B (2010 version)","volume":"19","year":"2011","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jhep.2009.04.003","article-title":"Antiviral therapy of chronic hepatitis B: opportunities and challenges in Asia","volume":"51","author":"YF Liaw","year":"2009","journal-title":"J Hepatol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12072-008-9080-3","article-title":"Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update","volume":"2","author":"YF Liaw","year":"2008","journal-title":"Hepatol Int"},{"key":"ref10","unstructured":"Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.bjstats.gov.cn\/Accessed\" xlink:type=\"simple\">http:\/\/www.bjstats.gov.cn\/Accessed<\/ext-link> 2014 Sep 17."},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Liaw YF, Kao JH (2012) Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int: 531\u2013561.","DOI":"10.1007\/s12072-012-9365-4"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1111\/j.1524-4733.2009.00636.x","article-title":"Assessment of Total Economic Burden of Chronic Hepatits B (CHB)-Related Disease in Beijing and Guangzhou, China","volume":"12","author":"H Min","year":"2009","journal-title":"Value in health"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s12072-008-9059-0","article-title":"Current approaches for treating chronic hepatitis B: when to start, what to start with, and when to stop","volume":"2","author":"TT Chang","year":"2008","journal-title":"Hepatol Int"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1872-034X.2011.00785.x","article-title":"Long-term outcome and hepatocellular carcinoma development in chronic hepatitis B or cirrhosis patients after nucleoside analog treatment with entecavir or lamivudine","volume":"41","author":"H Kobashi","year":"2011","journal-title":"Hepatol Res"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jhep.2009.04.007","article-title":"Treatment with nucleos(t)ide analogues in chronic hepatitis B: where does the road map lead us","volume":"51","author":"HL Janssen","year":"2009","journal-title":"J Hepatol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2147\/IDR.S4188","article-title":"Safety and efficacy of entecavir for the treatment of chronic hepatitis B","volume":"4","author":"M Osborn","year":"2011","journal-title":"Infect Drug Resist"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/MEG.0b013e3283511287","article-title":"Efficacy and safety of entecavir in clinical practice in treatment-naive Caucasian chronic hepatitis B patients","volume":"24","author":"M Buti","year":"2012","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1440-1746.2010.06545.x","article-title":"Treatment of chronic hepatitis B: Evolution over two decades","volume":"26","author":"MF Yuen","year":"2011","journal-title":"J Gastroenterol Hepatol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1055\/s-2003-37590","article-title":"Natural history and prognosis of hepatitis B","volume":"23","author":"G Fattovich","year":"2003","journal-title":"Semin Liver Dis"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0168-8278(01)00266-5","article-title":"Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study","volume":"36","author":"MR Brunetto","year":"2002","journal-title":"J Hepatol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1136\/gut.46.3.420","article-title":"Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep)","volume":"46","author":"G Fattovich","year":"2000","journal-title":"Gut"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1097\/MCG.0b013e31821f8bdf","article-title":"Comparison of clevudine and entecavir for treatment-naive patients with chronic hepatitis B virus infection: two-year follow-up data","volume":"45","author":"EL Yoon","year":"2011","journal-title":"J Clin Gastroenterol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/hep.23952","article-title":"Tenofovir disoproxil fumarate (TDF), emtricitabine\/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease","volume":"53","author":"YF Liaw","year":"2011","journal-title":"Hepatology"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0109652","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T23:50:01Z","timestamp":1588981801000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0109652"}},"subtitle":[],"editor":[{"given":"Xiaoping","family":"Miao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,10,16]]},"references-count":23,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2014,10,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0109652","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,16]]}}}